{"name":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","slug":"persongen-biotherapeutics-suzhou-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"gdT cell injection targeting B7-H3 chimeric antigen receptor","genericName":"gdT cell injection targeting B7-H3 chimeric antigen receptor","slug":"gdt-cell-injection-targeting-b7-h3-chimeric-antigen-receptor","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"gdT cell injection targeting B7-H3 chimeric antigen receptor","genericName":"gdT cell injection targeting B7-H3 chimeric antigen receptor","slug":"gdt-cell-injection-targeting-b7-h3-chimeric-antigen-receptor","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxNd19MU1pGNFQ3STFRb2k0cjB1UXRxY250cHZFY1dYeGlRMC01bFMwUURNUmFoU2dTSjdaV3pXeVFRVUpBNjJRbGtnYzY4ZjF4elhGTFgtV1JmTlhyMzVKc29SeW5iVW5UQU9BLVUzaEQ5bHNNSkx5Zm1BTC1Eb1FXaGRrY3JfcUxEVGdUOE1CWDEzR21jbUhHQ1Y1ZUpCRTRvd3Y5QXdkVFdVQlQtWXZhcXU1RUJfOHB2NDVwQUtsMGtEQkw0SEdwWmhXTVV1VWloMkZHZ0lNemRnSXNoWUlocGl6V244VUhrZWp2U0NiU0xxWElYZkJybjRKOW5TaHJZWTVFVmJFYnZaaF9PLS14SXludm9MQW1WWUlBLVVQRmptakNjczZxcTlhTVRkWTFEMmVuUzlPZEJPOVRYb2hoN1Q1WU9tdlE?oc=5","date":"2026-03-30","type":"pipeline","source":"globenewswire.com","summary":"Neuroblastoma Market Analysis Report 2026-2030 | Rising - globenewswire.com","headline":"Neuroblastoma Market Analysis Report 2026-2030 | Rising","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFRWdk1faWotclNmbkphcC1XeHJ0R0s0UnkyYnF6LVBrQjEycDZJSERQZnk4ZktwUTBHbG1wVTFSU1FxOHVTWUx3WTFnd2I3VlpnWDVEbUVEU05NN29zWlA3ZkFkMWU3YmotRno2S29NdUhWRTJadnc3SzFacVhnTjRwODJENnZXYVh4QzYxSjIwMG4zMnNjaG94VXdRellLZW5PbkpwTnY5RGl3VTlpUW5jYmtDb09iTTg5RHQ0ZG9tTDl0Zk1GQV9nS1R5WUxsOXpkeWtRcURYVEJvQ0dmNnZZSXlYUnBobk1PYw?oc=5","date":"2025-10-06","type":"pipeline","source":"PR Newswire","summary":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQd2pnNl93NVIwN3dSMmpYSGNmQVMxZ2Z2SFRGSi1JN1A0aTFuWFRFRDVsN1VmT2Z1UW1WT0QzUXYwSXptQ3lIRTZ3ZDRJc3NVdnI5ZVFZQ3BSSlRHLWU2Z2RzY1Fwa3RjcGhSdERtMU1IanNqajJVRnJnd0dwMHRaRTU5MG9UR2lPeHJUODd2Nk95OWQ0Smx3bGdIc1ZCMEUtUkxxakVyY2NvU1BfZ3RWQ2xfNFpBcVRfQUVHM1Nvd2dIMWR0cTdVd0p0RHBuN3pzNkFHd3Rrc1ctTWlBVFRxcDFxLUJadUExRzkxNHJjQnZzUl9WSGZzMnBkZXFWQ2FrN0I0eHJNNnM?oc=5","date":"2025-08-14","type":"pipeline","source":"PR Newswire","summary":"Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight - PR Newswire","headline":"Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNdGJiX1hIRnBfajZ4OUVpTXN3X1RHTUNnT1RLdUFOSGlGbHN5NjVnbll1a1h4UEVpNjNHcURnUF9xb1pVM2pwX2JVVFlnWHh6SU9LOFh3U0Zwd1FXZmxpVXpvbHZtcGRhTU14YmxudmF3azRzckJlYUpvZ2dlN2NJbTFPYkdIaTFLVHhOTTZBZWRSNlB5LTQ5UnJOeHlGeUpaVTkwNERUYi02blpuUHhPdjhBZ3p6NTRLTlNLdFZ5Slh6YVlCblhXTGdzYjNEMHMwY0ZwZDV0MDBoU3p5V1RQTnpHb1I1NUJmTGotckNWZzQwSFdTVUdYaFc4S29yWWc5Q1pnTTZib1VxLTRHSmUzbUprc0c1OEdpN2JtZzd1MUxLMm1SNDhjMERR?oc=5","date":"2025-07-07","type":"trial","source":"globenewswire.com","summary":"Bispecific Antibody Clinical Trial Pipeline Gains Momentum: - globenewswire.com","headline":"Bispecific Antibody Clinical Trial Pipeline Gains Momentum:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQV1JBcWNmYk85cFJyVU9PYzE1c0x3b2RjcW9fN1JUQ1FNc1BRUjNMRkltMTl3cHZCdnpoOHFvQlFCY3BrQ0ZWa1lxQnNCb055NlZyVlcwelZGd1hxRmhCVnBybXdSS1B3eFJZT1JUV0JfWGFEM2Vvc3ZJNzdRdUlPcmR4YkJjSEEyWGhIYm0xZkk0cXJLTzNXeXR3anY5cjA4eEQwbzNVWjUtSWxDdm55Ti0zWFh3TW8zUnlRcmpVTFhQc0NCMmJydTdVUzBYbXdGbGR5R2xPeWNLX3VuV0t6bWduNW1GYnhSYl8zbmFfa2lteDBGTzNtQUlKNHlOczZjYXFISHdpc3dtUm9IY0FCNmQwZ2hPeEhYdTAwaFFwTXlGd2Z4NHdpbUxiZXU1dGM5UjBrVjQ2UTc5QlJkM0NyUVlQWnBQTkU?oc=5","date":"2025-03-05","type":"trial","source":"globenewswire.com","summary":"CAR T-cell Therapy Clinical Trial Pipeline Experiences - globenewswire.com","headline":"CAR T-cell Therapy Clinical Trial Pipeline Experiences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-09-28","type":"pipeline","source":"PR Newswire","summary":"Neuroblastoma Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032), Examines DelveInsight | Key Companies to Watch - Y-mAbs, Exelixis, Clarity, Eli Lilly, Innervate Radio","headline":"Neuroblastoma Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032), Examines DelveInsight ","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}